Leavitt Partners, an HMA Company, is pleased to announce that Elaine Lippmann, J.D., has joined the firm as a principal, located in Washington, D.C. Lippmann joins recently hired former U.S. Food and Drug Administration (FDA) leader Julie Tierney on an expert team of health policy and government affairs consultants at Leavitt Partners. Collectively, our bipartisan team provides life sciences stakeholders with a unique combination of federal policy, regulatory, advocacy, private sector, and stakeholder experience. Learn more about Leavitt Partners’ FDA capabilities here.
Lippmann has more than 15 years of leadership experience at FDA and deep expertise in pharmaceutical regulatory policy. She is a strategic thinker whose deep understanding of FDA processes, drug law, and health policy will help life sciences stakeholders navigate uncertainty and complex challenges. Before her federal service, Lippmann practiced at a Washington, D.C. law firm, representing government and public agency clients in regulatory, transactional, and administrative litigation matters.
Lippmann most recently served as leadership in the Office of Regulatory Policy within the Center for Drug Evaluation and Research (CDER). In this role, she advised agency senior leadership on drug policy development, implementation, and strategy, and led a multidisciplinary team in advancing major regulatory and legal initiatives.
At Leavitt Partners, Lippmann will help life sciences companies, patient organizations, and others understand and develop regulatory strategies and advance policy solutions for complex issues throughout the product life cycle. Her focus on FDA regulatory strategy and policy builds on more than a decade of Leavitt Partners’ work helping clients drive FDA policy solutions to put safe and effective medicines into the hands of patients.
“We are excited to have Elaine bring her deep FDA agency experience and policy expertise in a wide range of issues central to the pharmaceutical industry, including approval pathways, post-market safety, product quality and compliance, artificial intelligence, and advanced manufacturing to our team,” said Josh Trent, chief executive officer of Leavitt Partners. “While we live in an era of increasingly personalized medicine and medical breakthroughs, the life sciences sector is facing a wide range of nuanced and interconnected policy, regulatory, and stakeholder complexities. Elaine brings her expertise to a team uniquely equipped to enhance our FDA-related services to help life sciences clients navigate the complexities of the evolving FDA policy, regulatory, and advocacy landscape.”
Lippmann joins a seasoned team of experts with significant experience drafting and implementing FDA laws and regulations and leading private sector life sciences solutions. The Leavitt Partners team includes former health policy directors and FDA subject matter experts from the U.S. Senate Budget Committee, the U.S. Senate Health, Education, Labor, and Pensions Committee, the U.S. House Energy and Commerce Committee, and other senior congressional offices. Leavitt Partners, founded by former HHS Secretary Michael O. Leavitt, includes former senior political appointees in Democratic and Republican presidential administrations, leaders formerly serving in several U.S. Department of Health and Human Services agencies, and former leaders in the non-profit and for-profit health sectors.
About Leavitt Partners
Leavitt Partners, an HMA Company, is a premier health policy and government affairs firm in Washington, D.C., that has been at the forefront of health policy development for more than a decade. Leavitt Partners helps clients understand and navigate the legislative and regulatory environments to create opportunities, resolve problems, direct action, and build and maintain positive interactions with key federal policymakers. Leavitt Partners is home to expert conveners with decades of experience in the private sector and government who have spent years fine-tuning the process for building successful alliances that bring multi-sector stakeholders to the table with a commitment to reaching consensus, real-world solutions.
About HMA
HMA is an independent, national research and consulting firm specializing in publicly funded healthcare and human services policy, programs, financing, and evaluation. We serve government, public and private providers, health systems, health plans, community-based organizations, institutional investors, foundations, and associations. With over 700 multidisciplinary consultants coast to coast, HMA’s expertise, services, and team are always within client reach. Our team of life sciences consultants are experts in federal and state policy, reimbursement strategy, actuarial services, medical coding support, public affairs, investment strategy, and corporate development. From early steps of research and development to product-specific communications and commercial and reimbursement strategies, we guide life sciences companies at every stage.